How Analysts Rated Affimed N.V. (NASDAQ:AFMD) Last Week?

November 10, 2018 - By Ann Prendergast

Affimed N.V. (NASDAQ:AFMD) Ratings Coverage

Among 2 analysts covering Affimed (NASDAQ:AFMD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Affimed had 3 analyst reports since August 9, 2018 according to SRatingsIntel. The company was maintained on Thursday, August 9 by BMO Capital Markets. The rating was upgraded by Jefferies on Tuesday, August 28 to “Buy”. The stock has “Outperform” rating by BMO Capital Markets on Tuesday, August 28. Below is a list of Affimed N.V. (NASDAQ:AFMD) latest ratings and price target changes.

28/08/2018 Broker: Jefferies Old Rating: Hold New Rating: Buy Old Target: $1.8 New Target: $4 Upgrade
28/08/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $4 New Target: $5 Maintain
09/08/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $6 New Target: $4 Maintain

The stock decreased 3.79% or $0.16 during the last trading session, reaching $4.06. About 845,659 shares traded. Affimed N.V. (NASDAQ:AFMD) has risen 126.19% since November 10, 2017 and is uptrending. It has outperformed by 110.57% the S&P500.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $253.46 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

More notable recent Affimed N.V. (NASDAQ:AFMD) news were published by: Seekingalpha.com which released: “Affimed Therapeutics (AFMD) CEO Adi Hoess on Q3 2018 Results – Earnings Call Transcript” on November 07, 2018, also Globenewswire.com with their article: “Affimed to Present at the Jefferies 2018 London Healthcare Conference” published on November 08, 2018, Nasdaq.com published: “Affimed Announces Oral Presentation and Five Poster Presentations at the 2018 American Society of Hematology …” on November 01, 2018. More interesting news about Affimed N.V. (NASDAQ:AFMD) were released by: Seekingalpha.com and their article: “Affimed Therapeutics 2018 Q3 – Results – Earnings Call Slides” published on November 07, 2018 as well as Globenewswire.com‘s news article titled: “Affimed Reports Financial Results for Third Quarter 2018 and Operational Progress” with publication date: November 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.